Indications: Alectinib Hydrochloride is prescribed for patients with metastatic non-small cell lung cancer (NSCLC) who have tested positive for the anaplastic lymphoma kinase (ALK) mutation and have either experienced disease progression on, or cannot tolerate, crizotinib treatment.

Pharmacology: Alectinib functions by inhibiting the ALK protein’s activity, which is present in certain cancer cells. This mechanism helps impede the growth of cancer cells.

Dosage and Administration: Typically, Alectinib Hydrochloride is administered orally at a recommended dosage of 600 mg twice daily. However, dosage adjustments may be necessary based on individual patient characteristics, as determined by a healthcare professional.

Interactions: Alectinib may interact with other medications, particularly those metabolized by the CYP3A enzyme system. Patients are advised to disclose all current medications, supplements, and herbal products to their healthcare provider to prevent potential interactions.

Side Effects: Common adverse effects of Alectinib include fatigue, constipation, muscle pain, peripheral edema, and rash. Patients should promptly inform their healthcare provider of any observed side effects.

Precautions and Warnings: Regular monitoring of liver function tests is recommended during Alectinib treatment due to the potential for liver issues. Additionally, patients should be monitored for bradycardia (slow heart rate) and interstitial lung disease.

Overdose Effects: In the event of overdose, supportive care should be administered. As there is no specific antidote for Alectinib overdose, treatment would focus on managing symptoms and providing appropriate support.